Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:38 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 16,128 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorders Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of Ocular Surface Changes Following RF Electrocoagulation Treatment of the Periorbital Region

NCT03280069
View directory record Official record
Conditions
Skin Laxity, Meibomian Gland Dysfunction
Interventions
THERMIeyes® 20 RF System
Device
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
40 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 1 Interventional

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

NCT02960594
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, ColoRectal Cancer, Gastric Cancer, Esophageal Cancer, HepatoCellular Carcinoma
Interventions
INO-1400, INO-9012, INO-1401
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Detroit, Michigan • Rochester, Minnesota • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Nov 3, 2026, 6:38 PM EST
Terminated Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

NCT00281294
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Fontolizumab
Drug
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 1 Interventional

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

NCT01245556
View directory record Official record
Conditions
Melanoma
Interventions
BMS-908662, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 4 Interventional Results available

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

NCT01119859
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Adalimumab, Placebo to tocilizumab, Placebo to adalimumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Nov 3, 2026, 6:38 PM EST
Completed No phase listed Observational

Fast Spectral Imaging Device for Tumor Margin Mapping

NCT01107080
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Nov 3, 2026, 6:38 PM EST
Withdrawn No phase listed Observational

Yervoy Pregnancy Surveillance Study

NCT02854488
View directory record Official record
Conditions
Melanoma
Interventions
Yervoy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Nov 3, 2026, 6:38 PM EST
Not listed Not applicable Interventional

Patient Experience and Quality of Patch Testing on the Legs vs Back

NCT06191627
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Patch testing
Diagnostic Test
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 1 Interventional

Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

NCT02122861
View directory record Official record
Conditions
Melanoma - Currently Enrolling, Non-small Cell Lung Cancer - Enrollment Completed, Sarcoma - Enrollment Completed
Interventions
ID-LV305
Biological
Lead sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 100 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
San Francisco, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 2 Interventional

Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study

NCT02300142
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg)
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Nov 3, 2026, 6:38 PM EST
Completed Not applicable Interventional Results available

Human Factors Testing for OTC Use of the Erchonia® LunulaLaser

NCT05626270
View directory record Official record
Conditions
Onychomycosis
Interventions
LunulaLaser OTC
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 2 Interventional

Adipose Derived Regenerative Cellular Therapy of Chronic Wounds

NCT02092870
View directory record Official record
Conditions
Diabetic Foot, Venous Ulcer, Pressure Ulcer
Interventions
Adipose derived stem cells
Drug
Lead sponsor
Tower Outpatient Surgical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Nov 3, 2026, 6:38 PM EST
Recruiting No phase listed Observational

The CorEvitas Psoriasis (PSO) Registry

NCT02707341
View directory record Official record
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2100
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 3, 2026, 6:38 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB

NCT05818254
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Contraception
Interventions
HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention, Routine Care
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 2 Interventional Results available

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00266110
View directory record Official record
Conditions
Breast Cancer
Interventions
sargramostim, therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Nov 3, 2026, 6:38 PM EST
Recruiting Not applicable Interventional

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

NCT07555210
View directory record Official record
Conditions
Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer), Non-Small Cell Lung Cancer, MSI-H/dMMR Rectal Cancer, Squamous Cell Carcinoma Mouth, Invasive Mammary Carcinoma, Classic Hodgkin Lymphoma
Interventions
Dual-Energy X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
Device
Lead sponsor
Jessica Mezzanotte Sharpe
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 3, 2026, 6:38 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

An Exploratory Investigation of a Novel Skincare Regimen

NCT05517720
View directory record Official record
Conditions
Wrinkle, Photoaging, Acne, Skin Inflammation
Interventions
Aria Trio complete Facial System
Other
Lead sponsor
Trophy Skin
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 1 Interventional

Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI

NCT00048620
View directory record Official record
Conditions
Mucopolysaccharidosis VI
Interventions
N-acetylgalactosamine 4-sulfatase
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2006 · Synced Nov 3, 2026, 6:38 PM EST
Not yet recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT07335562
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
16 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
17
States / cities
Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 3, 2026, 6:38 PM EST
Terminated Phase 1 Interventional

Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients

NCT01559103
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MEDI5117, MEDI5117 Placebo
Biological
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
20 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 3 Interventional Results available

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

NCT01537042
View directory record Official record
Conditions
Restless Legs Syndrome, End-Stage Renal Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Brandon, Florida • Newton, Massachusetts • West Seneca, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Nov 3, 2026, 6:38 PM EST
Completed No phase listed Observational

Oral Health Needs Assessment of Sjogren s Syndrome and Salivary Gland Dysfunction Cohorts and Healthy Volunteers Evaluating Oral Health Disparities as Determinants of Oral Health in a High-Risk Population

NCT03327870
View directory record Official record
Conditions
Sjogren's Syndrome, Oral Health
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections

NCT02150070
View directory record Official record
Conditions
Pharmacokinetics of ASP2408, Healthy Subjects
Interventions
ASP2408, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Nov 3, 2026, 6:38 PM EST